DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for choroid plexus papilloma — screening already-approved drugs against its 26-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChoroid plexus papilloma maps to a 26-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for choroid plexus papilloma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
A 1989 review of forty children with choroid plexus tumours operated on over 45 years reported that the five-year survival rate for children with choroid plexus carcinoma was 50%, with all deaths occurring within seven months of operation. Patients whose carcinomas were totally removed had a better prognosis than those with subtotal removal. The prognosis for children with papilloma was described as excellent. The authors concluded that the tumours are surgically treatable and that an aggressive surgical approach is justified, even for carcinoma.
A 1980 report of seventeen histologically verified choroid plexus papillomas stated that the surgical approach was not optimal. The authors illustrated that radiation therapy decreased the vascularity of tissue-proven papillomas and therefore aided operative removal. They presented limited experience with postoperative irradiation.
A 1954 journal article on papilloma of the choroid plexus provides no survival data, response rates, or sample sizes relevant to treatment outcomes. It is a case report that does not contain quantitative results.
No drug therapy is mentioned in any of these abstracts. What is still missing are prospective trials comparing surgical strategies, any controlled data on radiation timing or dosing, and any investigation of systemic therapies for recurrent or unresectable disease. Patient stratification by molecular subtype or genetic drivers has not been attempted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurosurgery · 1989 · 141 citations
Tumors of the Choroid Plexus in Children
AbstractAbstract Primary neoplasms of the choroid plexus in children are surgically treatable, and the encouraging results of surgical removal, even for carcinoma, justify an aggressive surgical approach, Forty cases operated on over a span of 45 years have been reviewed in detail, including a rereading of all microscopic slides. The prognosis for children with papilloma has been excellent. The 5-year survival rate for children with carcinoma of the choroid plexus was 50%, and all deaths occurred within 7 months of operation. The patients whose carcinomas were totally removed had a better prognosis than did those with subtotal removal.
Abstractp APILLOMAS of the choroid plexus are relatively rare and, including our present cases, a total of 143 have been reported to June 1960. The incidence at this clinic is 0.4 per cent of verified intracranial tumors. Since most reports in the literature have concerned one or two eases and because papillomas generally are considered to have a high surgical mortal i ty and a poor prognosis 7'1~ we felt tha t it may be of interest to present an analysis of 25 cases of papilloma treated in our clinic between the years 1926 and 1958. The literature pertinent to this subject has been reviewed on a number of occasions prior to 1953. 4,9,12,19,2~,~7
Treatment of Choroid Plexus Papillomas in Children
AbstractThis is a brief report of 17 histologically verified choroid plexus papillomas (CPPs). The radiological evaluation and surgical treatment are outlined. The results indicate that the surgical approach was not optimal. Radiation therapy decreasing the vascularity of tissue-proven CPPs and therefore aiding the operative removal is illustrated. The limited experience with postoperative irradiation is presented. The computed tomography of this lesion is discussed.
AbstractJournal Article Papilloma of the choroid plexus Get access L P Lassman L P Lassman Department of Neurological Surgery, Newcastle General Hospital, Newcastle-Upon-TyneRoyal Manchester Children's Hospital Search for other works by this author on: Oxford Academic Google Scholar British Journal of Surgery, Volume 41, Issue 168, January 1954, Pages 396–398, https://doi.org/10.1002/bjs.18004116817 Published: 06 December 2005
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
